RxDoctor Payments Data

Nnenna Okigbo, MD

Internal Medicine · Silver Spring, MDNPI 1538167028

Payments from drug & device makers

$2,950in general payments, 2019–2025

Across 140 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$771
  • Lilly USA, LLC$753
  • Boehringer Ingelheim$348
  • Novo Nordisk$312
  • Pfizer$190
  • Exact Sciences$136
  • plus $440 from 13 others

What the payments were for

  • Food & beverage$2,950100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,950 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$55,886
Medicare patients
124
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$53,589
OzempicSemaglutide29$32,346
JanuviaSitagliptin Phosphate20$19,221
TradjentaLinagliptin15$11,158
MounjaroTirzepatide11$8,537
Breo ElliptaFluticasone/Vilanterol12$4,944
Albuterol Sulfate HfaAlbuterol Sulfate70$2,347
Atorvastatin Calcium247$2,254
Fentanyl11$1,873
Amlodipine Besylate288$1,797
Potassium Chloride30$1,780
Metformin Hcl157$1,017
Gabapentin63$942
Alendronate Sodium88$814
Rosuvastatin Calcium30$772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$348$64,74759 claims
Novo NordiskOzempic$312$32,34629 claims
MerckJanuvia$116$19,22120 claims
Lilly USA, LLCMounjaro$753$8,53711 claims
GSKBreo Ellipta$56$4,94412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →